Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
about
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsThe CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-independent endocytosis pathways and thus regulates receptor signaling and recyclingThe Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1Diabetic rats present higher urinary loss of proteins and lower renal expression of megalin, cubilin, ClC-5, and CFTR.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedsideTeam work matters: dual inhibition puts non-hodgkin lymphoma under siege.Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.Signaling mechanisms regulating B-lymphocyte activation and tolerance.Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.AKT in cancer: new molecular insights and advances in drug development.Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance.Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.Phosphorylation-Dependent Inhibition of Akt1
P2860
Q26764833-F1FDF0D4-3550-490A-9745-2F3A033372B4Q30565546-93543F9F-2B49-489B-B778-80EE84B0C85AQ31070331-5CAE5B29-5CD5-43E0-B632-F51FF5DCFC7FQ33798463-4BCA15E3-FE37-4650-8E32-A4DFBFD662F0Q33896098-6D0FC133-93FF-440A-8264-F1EF5645871FQ33919290-CE4ACE7C-A1AF-4D49-AAF5-47FA472D74DCQ35582498-E09CF91B-38A7-4D6A-BB7C-8ECB0957878EQ35610195-8E903A10-EEB1-481F-85A2-1B8C8FD3C4E1Q36436997-244D00DE-CE0C-4B03-B094-83E07924884CQ36965860-D4CCA4BC-47D8-4BBB-9816-C58C31D95307Q38334794-7EC6CC07-5005-4D75-BB32-C8162887A47CQ38581826-AD3B8937-EEF9-4D38-891B-D7C1BADD7327Q38604547-44D9A81C-42DB-4427-B54D-5AD6E27571C6Q38790957-1A667559-7D19-4B47-8A03-3AF3DE09E97CQ38833567-99A6B6C1-7106-4235-89D2-3AB453D6C2FFQ38846044-24CF5359-0AB0-4CA5-A9CA-0A0F3F5957E0Q38903921-CD8E1A52-77E5-4B07-9D4E-C4F599B4AF1AQ38939419-8689BFFE-093E-4555-9491-DFA8E23CAE48Q39933783-E631955C-B5C9-49A1-9C4D-D260DC81F937Q41665957-2A059BA3-0EEA-4B7D-9663-F5815DD3DC03Q46579453-CB3BF102-409E-4EA5-B201-5702610D107DQ47110316-E191D2E8-E45A-4463-9FA7-D73498F8212DQ50308754-A7B36C6C-48AD-4866-9862-D5D739C4A0BDQ51682819-85B3BD97-7F75-4D09-9347-A32E795537A9Q58758462-E906F563-234D-44ED-AE3F-89980187B518
P2860
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
@en
type
label
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
@en
prefLabel
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
@en
P2860
P356
P1476
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
@en
P2093
Robert A Baiocchi
P2860
P356
10.1111/BJH.13065
P407
P577
2014-08-06T00:00:00Z